June 27, 2006 -- Genentech stopped a trial of Avastin for pancreatic cancer when Avastin did not provide a benefit; Barr Labs made a $2.2 billion bid to acquire Pliva of Croatia; Cephalon reported Gabitril failed a trial against generalized anxiety disorder; Hollis-Eden is in the hunt to supply Neumune to Project Bioshield; Amylin struck a deal with Nastech to develop a nasal-spray version of Byetta, the insulin substitute; Metabasis bought the PTP-1B program from Cengent Therapeutics; and Insmed presented data showing the effectiveness of Iplex. The Centient Biotech 200™ fell 46 points to 3526.59, a loss of 1.29%. More details...
